Novavax falls on production delay report, but this analyst expects good sales in the future

Oppenheimer analyst Hartaj Singh discusses the latest developments in the vaccine space, the state of biotech and why he thinks despite the recent selloff in Novavax, the company will deliver good sales in 2023 and beyond.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting